Venkatesan Sundaresan, a Distinguished Professor of plant biology and plant sciences at the University of California, Davis, ...
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ...
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
Venkatesan Sundaresan, a Distinguished Professor of plant biology and plant sciences at the University of California, Davis, ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Using CRISPR co-culture screens, researchers found that deleting CHD1 and MAP3K7 makes tumor cells more vulnerable to immune ...
Advancements in genome editing technologies the growing emphasis on safe and accurate gene correction, and strong biotechnology R&D investment drive the base editing market.Austin, Texas, Jan. 21, ...
The "Mice Model Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Mice Model ...
In Argentina, equine cloning in polo is no longer a rarity. It’s now a mature industry — although ethical dilemmas ...
A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malignancies, today announced that it has received ...
New one-dose treatment edits a gene in the liver, disabling the ANGPTL3 protein and significantly lowers cholesterol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results